Sihuan Pharmaceutical Holdings Group Ltd
Company Profile
Business description
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the medicine and other medicine segments; and the generic medicine segment which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
Contact
Zhubang 2000
22nd Floor, Building 4
West Balizhuang, Chaoyang District
Beijing100025
CHNT: +86 1057693700
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
2,767
Stocks News & Analysis
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
stocks
Magellan Financial Group: A dilutive acquisition of Barrenjoey
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,297.20 | 103.50 | -1.10% |
| CAC 40 | 8,394.32 | 186.43 | -2.17% |
| DAX 40 | 24,638.00 | 646.26 | -2.56% |
| Dow JONES (US) | 48,904.78 | 73.14 | -0.15% |
| FTSE 100 | 10,780.11 | 130.44 | -1.20% |
| HKSE | 25,959.16 | 100.69 | -0.39% |
| NASDAQ | 22,748.86 | 80.64 | 0.36% |
| Nikkei 225 | 56,423.30 | 1,633.94 | -2.81% |
| NZX 50 Index | 13,620.21 | 36.44 | -0.27% |
| S&P 500 | 6,881.62 | 2.74 | 0.04% |
| S&P/ASX 200 | 9,077.30 | 90.80 | -0.99% |
| SSE Composite Index | 4,161.91 | 20.68 | -0.49% |